Item 8.01. Other Events.

On January 24, 2023, Galera Therapeutics, Inc. (the "Company") received a letter from The Nasdaq Stock Market LLC ("Nasdaq") stating that (i) the Nasdaq Listing Qualifications staff had determined that the Company had regained compliance with the minimum Market Value of Listed Securities ("MVLS") of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the "MVLS Requirement"), (ii) the Company is therefore in compliance with all Nasdaq Global Market listing requirements, (iii) the hearing before the Nasdaq Hearings Panel ("Panel") scheduled for January 26, 2023 has been cancelled, and (iv) as a result, the Company's securities will continue to be listed and traded on The Nasdaq Global Market.

As previously reported, on December 6, 2022, the Company received a letter from Nasdaq indicating that the Company had not regained compliance with the MVLS Requirement during the 180-day compliance period that ended on December 5, 2022, and that, unless the Company requested a hearing before a Panel to appeal Nasdaq's delisting determination by 4:00 p.m. Eastern Time on December 13, 2022, trading of the Company's common stock will be suspended at the opening of business on December 15, 2022, and the Company's common stock would be delisted from The Nasdaq Global Market. The Company requested a hearing, which was scheduled for January 26, 2023.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses